Abbott has announced that its ILUMIEN IV OPTIMAL PCI (ILUMIEN IV) clinical study has demonstrated that intravascular imaging through optical coherence tomography (OCT) can enhance stent procedural outcomes, especially in complex cases.

Late-breaking data from the randomised global imaging study showed that during percutaneous coronary interventions (PCI), using OCT guidance compared to angiography enables physicians to achieve improved stent expansion, resulting in a greater minimal stent area (MSA).

Patients with medication-treated diabetes and complex artery disease were exclusively included in the study.

The study demonstrated that OCT guidance resulted in a statistically significant 7% rise in MSA compared to angiography guidance alone.

OCT guidance led to a 64% decrease in stent thrombosis (ST) rates, showing a significant statistical difference against angiographic guidance.

The study achieved its primary imaging endpoint of improving MSA.

However, it failed to attain superiority in lowering the primary clinical endpoint, target vessel failure (TVF), which is a composite of cardiac death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two years.

Abbott Vascular Business global medical affairs divisional vice-president and chief medical officer Nick West said: “The ILUMIEN IV data demonstrate the impact that OCT guidance can have when treating patients with complex coronary disease.

“In these cases, angiography alone simply cannot match the precision afforded by OCT to determine a treatment plan.”

The company’s latest OCT offering, Ultreon Software, is claimed to be the only intracoronary imaging solution on the market powered by artificial intelligence, guiding stents to place with precision.